Why Kids’ COVID-Vaccine Results Don’t Look Like Adults’

Lakshmi Ganapathi’s kid turned 5 on Friday, making him eligible for his first Pfizer COVID shot.

Ganapathi’s family had been looking forward to that moment for over a year, but she’s been feeling a little let down lately.

At first, the slow rollout of COVID vaccinations appeared worthwhile because the doses were so effective at preventing symptoms.

The clinical trials continued to provide stunning results: 94 percent efficacy, 95 percent efficacy, 100 percent efficacy, 91 percent efficacy—near-perfect performance in every studied group, from adults to elementary-school-age children.

Then Omicron swooped in, sneaking beyond the vaccinations’ protective barriers.

Research examining Pfizer’s vaccine, the only one accessible to American children, began to see a reduction in protection, particularly in children under the age of 12,

who receive a lesser dose and haven’t yet been urged to boost. Moderna, which apparently aims to seek FDA approval for its own kid-size injectable in mid-April,

has also shown mediocre results: In clinical studies, the vaccination only prevented symptomatic disease 40% of the time, owing in part to Omicron’s antibody-dodging abilities.

To Know Why Kids’ COVID-Vaccine Results Don’t Look Like Adults’ and how effective are kids covid vaccines.Please read our full article by clicking below.